[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557207":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":18,"locations":28,"responsibleParty":61,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"acute myeloid leukemia (AML) patients treated in the clinical units",null,[12],"Other: Clinical Practice",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":10},"Clinical Practice","All the procedures in Study will be conducted as per Clinical practice for the pathology and all the samples will be collected according to ELN guidelines.\n\nThere are no additional procedures but will be additionally collected up 20ml of peripheral blood and up to 15ml of Bone Marrow Aspirate at the same time of clinically indicated diagnostic procedures.",[9],[19,24],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Sara Mastaglio, Haematologist MD","CONTACT","+39 0226433917","ciceri.clinicaltrials@hsr.it",{"name":25,"role":21,"phone":26,"phoneExt":10,"email":27},"Vincenzo Mercurio, Ph.D Trial Office Coordinator","+390226439396","regolatorio.scp@hsr.it",[29,48],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"GOM Bianchi Melacrino Morelli","RECRUITING","Reggio Calabria","Calabria","89133","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],15.66129,38.11047,{"lat":41,"lon":40},[44],{"name":45,"role":21,"phone":46,"phoneExt":10,"email":47},"Massimo Martino, MD Ph.D Director","+39 0965393885","massimo.martino@ospedalerc.it",{"facility":49,"status":31,"city":50,"state":50,"zip":51,"country":35,"countryCode":36,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"IRCCS Ospedale San Raffaele","Milan","20132",{"type":38,"coordinates":53},[54,55],9.18951,45.46427,{"lat":55,"lon":54},[58],{"name":59,"role":21,"phone":60,"phoneExt":10,"email":23},"Sara Mastaglio, MD Haematologist","+39 0226439396",{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ciceri Fabio","Prof. MD Director",[66],{"name":67,"class":6},"Azienda Ospedaliera Bianchi-Melacrino-Morelli","100557207","decoding-the-inflammasome-influence-on-treatment-response-in-acute-myeloid-leukemia-100557207",false,"NCT06535113","Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia","Inflamm-AML","Inclusion Criteria:\n\n* Any gender,\n* Adults (\\>18 years old),\n* New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)\n* Capable of comprehend the study and the consent form,\n* Willing to sign the informed consent for the study.\n\nFor the retrospective population we will select:\n\nbiological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01\u002F06\u002F2006 up to 01\u002F06\u002F2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.\n\nExclusion Criteria:\n\n* Pediatric patients (\\\u003C18 years old),\n* Patients unable or unwilling to sign the informed consent.","ALL","18 Years",{"count":78,"type":79},80,"ESTIMATED","OBSERVATIONAL","The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.",[83],"Acute Myeloid Leukemia",[85,86,87,88],"Leukemia","Chemotherapy","inflammation","transplant","2026-06-04",{"date":91,"type":92},"2026-06-08","ACTUAL",{"date":94,"type":92},"2025-02-22",{"date":96,"type":79},"2026-08-31",{"name":63,"class":6},2]